ESC 2017: The Interleukin-1β Inhibitor Canakinumab Cuts Cardiovascular Disease and Lung Cancer Risk by Reducing Inflammation - CANTOS Trial
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles: